Dataset Information

Oral contraceptive and breast cancer: do benefits outweigh the risks? A case - control study from Jordan.

ABSTRACT:

Background

Oral contraceptives (OCs) use has been linked to increased risk of breast cancer (BC) in several reports from the world. Limited number of similar studies have been conducted in the Middle Eastern female population. This study aimed to explore any possible correlation between the contemporary and duration of OCs use among Jordanian women and the risk of breast cancer.

Methods

A case control study was conducted in 450 Jordanian women (225 as cases and 225 as controls), aged 18 to 65. Chi-square test was used to study the association between risk of breast cancer and different factors. Mann Whitney-U test was employed to evaluate the relation between time-dependent risk factor and breast cancer.

Results

Our results indicated that regular use of OCs exhibited association with increased risk of breast cancer (OR?=?2.25, 95% CI 1.34-2.79; p?=?0.002), while the duration of OCs use was not associated with the increased risk of breast cancer (p?>?0.05). In addition, other factors demonstrated significant association with the increased risk of breast cancer such as age at puberty, age at menopause, previous pregnancies, menopausal status, and family history of cancer.

Conclusions

regular use of OCs may be associated with increased risk of breast cancer in Jordanian women. A larger sample size in multi-center setting study is required to confirm this finding among the Jordanian female population.

SUBMITTER: Bardaweel SK

PROVIDER: S-EPMC6547482 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Oral contraceptive and breast cancer: do benefits outweigh the risks? A case - control study from Jordan.

Bardaweel Sanaa K SK Akour Amal A AA Al-Muhaissen Suha S AlSalamat Husam A HA Ammar Khawlah K

BMC women's health 20190603 1

<h4>Background</h4>Oral contraceptives (OCs) use has been linked to increased risk of breast cancer (BC) in several reports from the world. Limited number of similar studies have been conducted in the Middle Eastern female population. This study aimed to explore any possible correlation between the contemporary and duration of OCs use among Jordanian women and the risk of breast cancer.<h4>Methods</h4>A case control study was conducted in 450 Jordanian women (225 as cases and 225 as controls), a ...[more]

PMID: 31159800

Similar Datasets

Project description:Oral contraceptives are known to influence the risk of cancers of the female reproductive system. Evidence regarding the relationship between injectable contraceptives and these cancers is limited, especially in black South Africans, among whom injectable contraceptives are used more commonly than oral contraceptives.We analysed data from a South African hospital-based case-control study of black females aged 18-79 y, comparing self-reported contraceptive use in patients with breast (n?=?1,664), cervical (n?=?2,182), ovarian (n?=?182), and endometrial (n?=?182) cancer, with self-reported contraceptive use in 1,492 control patients diagnosed with cancers with no known relationship to hormonal contraceptive use. We adjusted for potential confounding factors, including age, calendar year of diagnosis, education, smoking, alcohol, parity/age at first birth, and number of sexual partners. Among controls, 26% had used injectable and 20% had used oral contraceptives. For current and more recent users versus never users of oral or injectable contraceptives, the odds ratios (ORs) for breast cancer were significantly increased in users of oral and/or injectable contraceptives (OR 1.66, 95% CI 1.28-2.16, p<0.001) and separately among those exclusively using oral (1.57, 1.03-2.40, p?=?0.04) and exclusively using injectable (OR 1.83, 1.31-2.55, p<0.001) contraceptives; corresponding ORs for cervical cancer were 1.38 (1.08-1.77, p?=?0.01), 1.01 (0.66-1.56, p?=?0.96), and 1.58 (1.16-2.15, p?=?0.004). There was no significant increase in breast or cervical cancer risk among women ceasing hormonal contraceptive use ?10 y previously (p?=?0.3 and p?=?0.9, respectively). For durations of use ?5 y versus never use, the ORs of ovarian cancer were 0.60 (0.36-0.99, p?=?0.04) for oral and/or injectable contraceptive use and 0.07 (0.01-0.49, p?=?0.008) for injectable use exclusively; corresponding ORs for endometrial cancer were 0.44 (0.22-0.86, p?=?0.02) and 0.36 (0.11-1.26, p?=?0.1).In this study, use of oral and of injectable hormonal contraceptives was associated with a transiently increased risk of breast and cervical cancer and, for long durations of use, with a reduced risk of ovarian and endometrial cancer. The observed effects of injectable and of oral contraceptives on cancer risk in this study did not appear to differ substantially.

Dataset Information

Oral contraceptive and breast cancer: do benefits outweigh the risks? A case - control study from Jordan.

Background

Methods

Results

Conclusions

Publications

Oral contraceptive and breast cancer: do benefits outweigh the risks? A case - control study from Jordan.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets